Spero Therapeutics, Inc. (SPRO)
After hours:
| Previous Close | 1.4800 |
| Open | 1.4600 |
| Bid | 1.4500 x 400 |
| Ask | 1.5200 x 100 |
| Day's Range | 1.4500 - 1.5001 |
| 52 Week Range | 0.9900 - 1.8900 |
| Volume | |
| Avg. Volume | 310,362 |
| Market Cap | 79.36M |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 3.42 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the H.C. Wainwright 2nd Annual BioConnect Investor
- GlobeNewswire
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE)
- GlobeNewswire
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference cal
